CXCL8 and COVID-19: A murine model of COVID-19 immunopathology blocking IL-8-like signaling with reparixin resulted in a trend towards clinical improvement of hACE2 mice at 24 h, reduced fibrinogen binding by intravascular neutrophils and attenuation of spike protein-induced pulmonary microthrombosis (Kaiser et al., 2021).